• CRISPR Therapeutics AG recently reported past second‑quarter 2026 results showing revenue rising to US$10.18 million and its net loss shrinking to US$91.15 million, while extending CASGEVY’s FDA approval to children as young as two.
• Alongside these figures, the company highlighted fresh momentum in its gene‑editing pipeline, initiating new in vivo trials across cardiovascular, autoimmune, and oncology indications.
• Against this backdrop, we’ll examine how stronger CASGEVY traction and early‑stage pipeline progress shape CRISPR Therapeutics’ investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is CRISPR Therapeutics' Investment Narrative?

To own CRISPR Therapeutics, you have to believe that CASGEVY can grow into a meaningful commercial franchise while the in vivo and cell therapy pipeline eventually justifies years of heavy losses. The latest quarter nudges that thesis forward: revenue is still small in absolute terms at US$10.18 million, but CASGEVY’s broader FDA label and the start of new trials in cardiovascular, autoimmune, and oncology programs give investors more concrete near term catalysts than before. At the same time, the business remains firmly loss making, with a US$91.15 million quarterly net loss and a history of tapping equity markets, so funding and execution risk have not gone away. Given the share price has only inched around breakeven over three years, this update matters, but it does not remove the core uncertainties around long term adoption and clinical success.

However, one issue still stands out that investors should not ignore. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Investors in the Simply Wall St Community currently see fair value anywhere between about US$87 and just over US$217 across 4 estimates, so opinions are clearly spread. Set that against CRISPR Therapeutics’ widening but still early stage pipeline and ongoing heavy losses, and you can see why different shareholders may focus on very different outcomes for the business over time.

Explore 4 other fair value estimates on CRISPR Therapeutics - why the stock might be worth over 4x more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.